BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16470120)

  • 1. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality.
    Wyatt CM; Arons RR; Klotman PE; Klotman ME
    AIDS; 2006 Feb; 20(4):561-5. PubMed ID: 16470120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection.
    Butt AA; Fultz SL; Kwoh CK; Kelley D; Skanderson M; Justice AC
    Hepatology; 2004 Jul; 40(1):115-9. PubMed ID: 15239093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era.
    Kramer JR; Giordano TP; Souchek J; El-Serag HB
    J Hepatol; 2005 Mar; 42(3):309-14. PubMed ID: 15710213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis.
    Lopes JA; Melo MJ; Viegas A; Raimundo M; Câmara I; Antunes F; Gomes da Costa A
    Nephrol Dial Transplant; 2011 Dec; 26(12):3888-94. PubMed ID: 21543659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
    Katsarou O; Touloumi G; Antoniou A; Kouramba A; Hatzakis A; Karafoulidou A
    Haemophilia; 2005 Jul; 11(4):360-5. PubMed ID: 16011588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
    AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.
    Choi AI; Rodriguez RA; Bacchetti P; Volberding PA; Havlir D; Bertenthal D; Bostrom A; O'Hare AM
    Clin Infect Dis; 2007 Dec; 45(12):1633-9. PubMed ID: 18190326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population.
    Ormaasen V; Sandvik L; Dudman SG; Bruun JN
    Scand J Infect Dis; 2007; 39(1):51-7. PubMed ID: 17366013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antiretroviral therapy on admissions of HIV-infected patients to an intensive care unit.
    Palacios R; Hidalgo A; Reina C; de la Torre M; Márquez M; Santos J
    HIV Med; 2006 Apr; 7(3):193-6. PubMed ID: 16494634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients.
    Nuesch R; Geigy N; Schaedler E; Battegay M
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):684-7. PubMed ID: 12373504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy.
    Palacios R; Merchante N; Macias J; González M; Castillo J; Ruiz J; Márquez M; Gómez-Mateos J; Pineda JA; Santos J
    Antivir Ther; 2006; 11(4):529-35. PubMed ID: 16856627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile.
    Rajasekaran S; Raja K; Jeyaseelan L; Vijilat S; Priya K; Mohan K; Parvez A; Mahilmaran A; Chandrasekar C
    Indian J Tuberc; 2009 Apr; 56(2):69-76. PubMed ID: 19810588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased health care utilization and increased antiretroviral use in HIV-infected individuals with mental health disorders.
    Mijch A; Burgess P; Judd F; Grech P; Komiti A; Hoy J; Lloyd JH; Gibbie T; Street A
    HIV Med; 2006 May; 7(4):205-12. PubMed ID: 16630032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.